Alnylam Pharmaceuticals Biotech News Vir Biotechnology

Alnylam and Vir Expand Collaboration to Develop RNAi Therapeutics for Coronavirus Infection

Biotech News | 06.03.2020

Alnylam Pharmaceuticals and Vir Biotechnology expand their collaboration to advance siRNA...

Alnylam Pharmaceuticals Biotech News

Alnylam Reports Positive Phase 3 Results for its ILLUMINATE-A Trial of Lumasiran in Primary Hyperoxaluria

Biotech News | 17.12.2019

The US biotech company and specialist in RNA interference therapies Alnylam Pharmaceuticals today...

Alnylam Pharmaceuticals Biotech News

Alnylam Pharmaceuticals Initiates New Phase 3 Trial of Patisiran for the Treatment of Patients with Transthyretin Amyloidosis with Cardiomyopathy

Biotech News | 16.09.2019

Alnylam Therapeutics, a leading RNA interference company and member of our Biotech Investments...